OKYO Pharma Limited (“OKYO” or the “Company”) to File IND in Q3 2022 for OK-101 to treat Dry Eye Disease (“DED”) and to go directly to a Phase 2 Human Clinical Efficacy
Get inside Wall Road with StreetInsider Premium. Declare your 1-week free trial here. LONDON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- ...
